
|Articles|July 1, 2003
VISX gets OK from FDA; investors block takeover
Santa Clara, CA-VISX Inc. is celebrating the FDA approval of its CustomVue laser-vision correction procedure, as its board survived an attempt to dethrone one member in a takeover plan by financier Carl C. Icahn.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: Arshad M. Khanani, MD, highlights 3-year results from the GATHER2 open-label extension trial
4
AAO 2025: Trial demonstrates safety and efficacy of epithelium-on cross linking
5